Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.

Long-term Activity Ratios (Summary)
Net Fixed Asset Turnover
Total Asset Turnover
Equity Turnover

Regeneron Pharmaceuticals Inc., long-term (investment) activity ratios (quarterly data)

	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015	Dec 31, 2014	Sep 30, 2014	Jun 30, 2014	Mar 31, 2014
Net fixed asset turnover	2.75	2.70	2.65	2.61	2.52	2.52	2.53	2.49	2.43	2.32	2.19	2.33	2.53	2.62	2.66	2.57	2.58	2.56	2.76	2.89	—	—	—
Total asset turnover	0.55	0.55	0.54	0.57	0.59	0.62	0.65	0.67	0.63	0.65	0.64	0.70	0.69	0.75	0.75	0.73	0.73	0.75	0.73	0.73	—	—	—
Equity turnover	0.73	0.74	0.73	0.77	0.81	0.86	0.92	0.96	0.91	0.95	1.02	1.09	1.05	1.14	1.18	1.12	1.16	1.02	1.03	1.11	—	—	—

Long-term activity ratio	Description	The company
Net fixed asset turnover	An activity ratio calculated as total revenue divided by net fixed assets.	Regeneron Pharmaceuticals Inc.’s net fixed asset turnover ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Total asset turnover	An activity ratio calculated as total revenue divided by total assets.	Regeneron Pharmaceuticals Inc.’s total asset turnover ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019.
Equity turnover	An activity ratio calculated as total revenue divided by shareholders’ equity.	Regeneron Pharmaceuticals Inc.’s equity turnover ratio improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019.

Regeneron Pharmaceuticals Inc., net fixed asset turnover calculation (quarterly data)

	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015	Dec 31, 2014	Sep 30, 2014	Jun 30, 2014	Mar 31, 2014
Selected Financial Data (US$ in thousands)
Revenues	2,048,400	1,933,700	1,711,800	1,927,797	1,663,496	1,608,022	1,511,485	1,582,447	1,500,673	1,470,116	1,318,991	1,226,827	1,220,122	1,212,629	1,200,849	1,098,077	1,137,422	998,617	869,612	802,329	725,788	665,700	625,740
Property, plant, and equipment, net	2,771,400	2,676,600	2,612,800	2,575,800	2,524,446	2,461,614	2,394,727	2,358,605	2,274,529	2,261,702	2,277,029	2,083,421	1,872,167	1,772,923	1,666,391	1,594,120	1,475,123	1,326,112	1,110,597	974,309	818,967	707,321	600,864
Long-term Activity Ratio
Net fixed asset turnover¹	2.75	2.70	2.65	2.61	2.52	2.52	2.53	2.49	2.43	2.32	2.19	2.33	2.53	2.62	2.66	2.57	2.58	2.56	2.76	2.89	—	—	—
Benchmarks
Net Fixed Asset Turnover, Competitors²
Abbott Laboratories	4.01	3.95	4.03	4.04	4.08	3.98	3.71	3.60	3.48	3.24	3.07	3.66	3.61	3.53	3.49	3.56	3.55	3.57	3.58	3.41	—	—	—
AbbVie Inc.	11.36	11.33	11.42	11.36	10.91	11.10	10.47	10.07	10.11	10.05	10.04	9.85	9.57	9.46	9.16	8.91	8.61	8.34	8.41	8.03	—	—	—
Allergan PLC	8.52	8.61	8.82	8.83	9.13	9.17	9.06	8.93	8.59	8.61	8.89	9.04	8.54	8.89	9.93	9.58	10.49	5.62	4.64	8.19	—	—	—
Amgen Inc.	4.55	4.58	4.59	4.54	4.51	4.48	4.44	4.37	4.45	4.41	4.41	4.41	4.39	4.41	4.36	4.27	4.17	3.98	3.87	3.70	—	—	—
Biogen Inc.	4.54	4.57	4.58	3.74	3.74	3.78	3.78	3.86	3.95	4.14	4.42	4.58	4.78	4.88	4.84	4.92	5.21	5.60	5.82	5.50	—	—	—
Bristol-Myers Squibb Co.	5.00	4.92	4.67	4.49	4.33	4.25	4.16	4.15	4.10	4.09	3.98	3.90	3.86	3.83	3.80	3.75	3.89	3.75	3.73	3.59	—	—	—
Eli Lilly & Co.	2.90	2.96	3.08	2.75	2.75	2.72	2.61	2.59	2.61	2.56	2.56	2.57	2.53	2.55	2.51	2.48	2.44	2.45	2.46	2.46	—	—	—
Gilead Sciences Inc.	5.03	5.16	5.31	5.41	5.76	6.23	7.11	7.79	8.72	9.31	9.80	10.45	11.48	12.29	13.34	14.13	14.45	15.12	15.30	14.62	—	—	—
Johnson & Johnson	4.79	4.72	4.80	4.79	4.89	4.85	4.62	4.50	4.47	4.41	4.46	4.52	4.45	4.44	4.40	4.41	4.53	4.61	4.79	4.61	—	—	—
Merck & Co. Inc.	3.22	3.20	3.19	3.18	3.27	3.27	3.24	3.23	3.27	3.31	3.32	3.31	3.32	3.29	3.19	3.16	3.19	3.19	3.21	3.22	—	—	—
Pfizer Inc.	3.87	3.97	4.00	4.01	3.80	3.83	3.77	3.79	3.89	3.91	3.97	3.97	4.01	3.84	3.75	3.55	3.50	4.22	4.26	4.22	—	—	—

¹ Q3 2019 Calculation
Net fixed asset turnover = (Revenues_{Q3 2019} + Revenues_{Q2 2019} + Revenues_{Q1 2019} + Revenues_{Q4 2018}) ÷ Property, plant, and equipment, net
= (2,048,400 + 1,933,700 + 1,711,800 + 1,927,797) ÷ 2,771,400 = 2.75

² Click competitor name to see calculations.

Long-term activity ratio	Description	The company
Net fixed asset turnover	An activity ratio calculated as total revenue divided by net fixed assets.	Regeneron Pharmaceuticals Inc.’s net fixed asset turnover ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Regeneron Pharmaceuticals Inc., total asset turnover calculation (quarterly data)

	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015	Dec 31, 2014	Sep 30, 2014	Jun 30, 2014	Mar 31, 2014
Selected Financial Data (US$ in thousands)
Revenues	2,048,400	1,933,700	1,711,800	1,927,797	1,663,496	1,608,022	1,511,485	1,582,447	1,500,673	1,470,116	1,318,991	1,226,827	1,220,122	1,212,629	1,200,849	1,098,077	1,137,422	998,617	869,612	802,329	725,788	665,700	625,740
Total assets	13,939,300	13,173,600	12,854,800	11,734,500	10,805,613	9,951,980	9,372,696	8,764,286	8,701,215	8,106,373	7,817,365	6,973,466	6,828,019	6,204,906	5,904,460	5,609,132	5,182,915	4,526,970	4,198,573	3,871,827	3,739,419	3,456,078	3,260,396
Long-term Activity Ratio
Total asset turnover¹	0.55	0.55	0.54	0.57	0.59	0.62	0.65	0.67	0.63	0.65	0.64	0.70	0.69	0.75	0.75	0.73	0.73	0.75	0.73	0.73	—	—	—
Benchmarks
Total Asset Turnover, Competitors²
Abbott Laboratories	0.46	0.45	0.45	0.46	0.42	0.43	0.40	0.36	0.35	0.33	0.31	0.40	0.52	0.52	0.51	0.49	0.49	0.46	0.47	0.49	—	—	—
AbbVie Inc.	0.55	0.57	0.58	0.55	0.49	0.50	0.43	0.40	0.40	0.40	0.40	0.39	0.38	0.37	0.44	0.43	0.40	0.39	0.77	0.72	—	—	—
Allergan PLC	0.17	0.16	0.16	0.16	0.15	0.15	0.14	0.13	0.13	0.12	0.12	0.11	0.09	0.10	0.12	0.11	0.12	0.12	0.09	0.25	—	—	—
Amgen Inc.	0.37	0.38	0.35	0.34	0.33	0.33	0.31	0.27	0.27	0.28	0.28	0.28	0.28	0.29	0.28	0.29	0.29	0.28	0.29	0.28	—	—	—
Biogen Inc.	0.52	0.54	0.52	0.53	0.52	0.54	0.48	0.52	0.51	0.54	0.54	0.50	0.52	0.52	0.53	0.55	0.51	0.61	0.67	0.68	—	—	—
Bristol-Myers Squibb Co.	0.42	0.43	0.67	0.64	0.65	0.66	0.64	0.62	0.61	0.61	0.61	0.58	0.55	0.54	0.53	0.52	0.52	0.51	0.48	0.47	—	—	—
Eli Lilly & Co.	0.60	0.60	0.63	0.56	0.54	0.56	0.53	0.51	0.52	0.54	0.57	0.55	0.55	0.56	0.58	0.56	0.54	0.54	0.55	0.53	—	—	—
Gilead Sciences Inc.	0.37	0.35	0.35	0.34	0.34	0.35	0.37	0.37	0.42	0.47	0.50	0.53	0.55	0.64	0.68	0.62	0.61	0.73	0.70	0.71	—	—	—
Johnson & Johnson	0.53	0.52	0.54	0.53	0.52	0.52	0.50	0.49	0.48	0.47	0.50	0.51	0.51	0.51	0.52	0.53	0.53	0.54	0.57	0.57	—	—	—
Merck & Co. Inc.	0.55	0.53	0.52	0.51	0.49	0.49	0.47	0.46	0.43	0.43	0.41	0.42	0.41	0.41	0.40	0.39	0.39	0.39	0.38	0.43	—	—	—
Pfizer Inc.	0.31	0.34	0.35	0.34	0.32	0.32	0.32	0.31	0.30	0.31	0.31	0.31	0.30	0.31	0.31	0.29	0.28	0.30	0.31	0.29	—	—	—

¹ Q3 2019 Calculation
Total asset turnover = (Revenues_{Q3 2019} + Revenues_{Q2 2019} + Revenues_{Q1 2019} + Revenues_{Q4 2018}) ÷ Total assets
= (2,048,400 + 1,933,700 + 1,711,800 + 1,927,797) ÷ 13,939,300 = 0.55

² Click competitor name to see calculations.

Long-term activity ratio	Description	The company
Total asset turnover	An activity ratio calculated as total revenue divided by total assets.	Regeneron Pharmaceuticals Inc.’s total asset turnover ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019.

Regeneron Pharmaceuticals Inc., equity turnover calculation (quarterly data)

	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015	Dec 31, 2014	Sep 30, 2014	Jun 30, 2014	Mar 31, 2014
Selected Financial Data (US$ in thousands)
Revenues	2,048,400	1,933,700	1,711,800	1,927,797	1,663,496	1,608,022	1,511,485	1,582,447	1,500,673	1,470,116	1,318,991	1,226,827	1,220,122	1,212,629	1,200,849	1,098,077	1,137,422	998,617	869,612	802,329	725,788	665,700	625,740
Stockholders’ equity	10,504,400	9,755,900	9,444,700	8,757,300	7,868,300	7,186,426	6,567,644	6,144,078	6,051,593	5,520,738	4,866,021	4,449,245	4,491,247	4,076,506	3,765,082	3,654,837	3,296,867	3,338,458	2,971,430	2,542,325	2,551,788	2,368,842	2,211,248
Long-term Activity Ratio
Equity turnover¹	0.73	0.74	0.73	0.77	0.81	0.86	0.92	0.96	0.91	0.95	1.02	1.09	1.05	1.14	1.18	1.12	1.16	1.02	1.03	1.11	—	—	—
Benchmarks
Equity Turnover, Competitors²
Abbott Laboratories	0.99	0.98	0.99	1.00	0.99	0.97	0.91	0.89	0.78	0.75	0.71	1.02	1.00	0.99	0.98	0.96	0.97	0.89	0.93	0.94	—	—	—
AbbVie Inc.	—	—	—	—	—	—	8.33	5.54	4.08	4.44	5.25	5.53	3.90	4.39	5.12	5.79	4.51	3.81	14.84	11.46	—	—	—
Allergan PLC	0.27	0.26	0.26	0.24	0.23	0.23	0.22	0.22	0.22	0.20	0.20	0.19	0.15	0.18	0.21	0.20	0.21	0.22	0.18	0.46	—	—	—
Amgen Inc.	2.04	2.07	2.07	1.80	1.54	1.48	1.40	0.86	0.68	0.69	0.71	0.73	0.70	0.72	0.74	0.75	0.74	0.73	0.75	0.75	—	—	—
Biogen Inc.	1.02	1.09	1.00	1.03	0.96	1.05	0.90	0.97	0.92	1.01	1.00	0.94	0.94	0.99	1.06	1.15	1.00	0.82	0.87	0.90	—	—	—
Bristol-Myers Squibb Co.	1.37	1.49	1.53	1.61	1.62	1.75	1.64	1.77	1.39	1.38	1.38	1.20	1.18	1.18	1.18	1.16	1.10	1.08	1.04	1.07	—	—	—
Eli Lilly & Co.	6.69	8.35	9.66	2.50	1.86	2.07	1.61	1.97	1.51	1.56	1.54	1.52	1.34	1.41	1.34	1.37	1.29	1.34	1.31	1.28	—	—	—
Gilead Sciences Inc.	1.07	0.97	1.00	1.01	0.96	1.05	1.18	1.26	1.09	1.24	1.40	1.59	1.85	2.06	2.42	1.73	1.78	1.76	1.57	1.59	—	—	—
Johnson & Johnson	1.40	1.34	1.38	1.37	1.26	1.28	1.24	1.27	1.01	1.01	1.03	1.02	0.98	0.98	0.97	0.98	0.99	1.01	1.08	1.07	—	—	—
Merck & Co. Inc.	1.71	1.61	1.56	1.58	1.29	1.27	1.21	1.17	1.04	1.01	1.00	0.99	0.91	0.91	0.90	0.88	0.87	0.87	0.87	0.87	—	—	—
Pfizer Inc.	0.81	0.90	0.92	0.85	0.75	0.76	0.72	0.74	0.86	0.90	0.90	0.89	0.84	0.83	0.81	0.75	0.72	0.72	0.73	0.70	—	—	—

¹ Q3 2019 Calculation
Equity turnover = (Revenues_{Q3 2019} + Revenues_{Q2 2019} + Revenues_{Q1 2019} + Revenues_{Q4 2018}) ÷ Stockholders’ equity
= (2,048,400 + 1,933,700 + 1,711,800 + 1,927,797) ÷ 10,504,400 = 0.73

² Click competitor name to see calculations.

Long-term activity ratio	Description	The company
Equity turnover	An activity ratio calculated as total revenue divided by shareholders’ equity.	Regeneron Pharmaceuticals Inc.’s equity turnover ratio improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019.

Regeneron Pharmaceuticals Inc. (REGN)

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Long-term Activity Ratios (Summary)

Net Fixed Asset Turnover

Total Asset Turnover

Equity Turnover

Regeneron Pharmaceuticals Inc. (REGN)

Analysis of Long-term (Investment) Activity RatiosQuarterly Data

Long-term Activity Ratios (Summary)

Net Fixed Asset Turnover

Total Asset Turnover

Equity Turnover

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data